January 5, 2017
by inesp.alves
5 Comments
A press release from Business Wire stated that Therachon AG, a biotechnology company focused on rare genetic diseases, announced today it has appointed Luca Santarelli, M.D., as Chief Executive Officer and Director, and raised more $5 million for new medicines R&D (research a … Continue reading
June 30, 2016
by inesp.alves
0 comments
In the present, achondroplasia has more opportunities in the scientific search for a treatment than almost any other rare disease has. And this is very amazing. There are some relevant points in the science that is being produced for achondroplasia: … Continue reading
October 20, 2014
by inesp.alves
4 Comments
In my last post, about the V International congress around achondroplasia and other skeletal dysplasia, I mentioned the participation of Dr. Elvire Gouze and her lecture. She is responsable for the developement of the soluble FGFR3. Dr. Elvire Gouze was kind to … Continue reading
July 4, 2014
by inesp.alves
1 Comment
I have been following for several months the search work of prof. Morrys Kaisermann around achondroplasia latest researchs. He keeps a blog about achondroplasia named “Acondroplasia-Achondroplasia” and his lastest post is a brilliant synopsis of the current achondroplasia potential treatments and … Continue reading
September 30, 2013
by inesp.alves
0 comments
With this simple scheme, I try to show the action of soluble FGFR3 in the growth plate, competing with mutated FGFR3 that exist in the cell membrane.
September 19, 2013
by inesp.alves
0 comments
This past few weeks, have been rich in new acknowledgments around achondroplasia treatment. Yesterday, a research team from Inserm, published the following article: Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice Abstract Achondroplasia is … Continue reading